Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DRUGseq U2OS cells treated with small molecules

ABSTRACT: We report the transcriptional changes associated with treatment of U2OS osteosarcoma cell line with DMSO, ND-09-QY33, CA-90-VK59, JC-68-AL90, MB-03-IE36, JC-43-ZO95, PA-33-CK45, KA-73-NB69, QC-05-UB63, SE-15-AV21, NV-67-DX31, DB-85-YA47, NA-37-JQ34, VA-76-OV33, & LD-22-SA99

ORGANISM(S): Homo sapiens

PROVIDER: GSE176150 | GEO | 2021/06/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

U2OS-ERa, U2OS-ERb, and U2OS-ERab cells treated with 4HT or E2

Project description:U2OS-ERa, U2OS-ERb, and U2OS-ERab cells treated with 4HT or E2 Keywords: other

2005-04-06 | GSE2292 | GEO

hTERT promotes cell adhesion and migration independent of telomerase activity

Project description:We sequenced mRNA from 6 human cell lines stably over-expressed specific gene or empty vector, and searched for differently expressed genes after gene over-expression as compared to empty vector. mRNA levels were compared as following pairs: U2OS+hTERT vs U2OS+vector; U2OS+hTERTmut vs U2OS+vector; VA-13+hTERT vs VA-13+vector; VA-13+hTERTmut vs VA-13+vector.

2015-09-22 | E-GEOD-73277 | biostudies-arrayexpress

Whole-genome CRISPR screen of etoposide-treated U2OS and U2OS p53KO cells, and RNAseq of U2OS cells incubated in media conditioned by etoposide-treated U2OS or U2OS p53KO cells.

Project description:CRISPR screen: U2OS or U2OS p53KO cells expressing Cas9 were transduced with a whole-genome library of CRISPR sgRNAs, then treated with either DMSO or etoposide. Differential sgRNA abundances were calculated for each condition and used to determine the effect of each single gene knockout on fitness and the drug-induced death rate. RNA-Seq: U2OS or U2OS p53KO cells were cultured with either DMSO or etoposide for 48 hours, and then U2OS cells were incubated in this conditioned media for 8 hours. RNA was collected and use to observe differential expression changes between conditions.

2023-05-17 | GSE232592 | GEO

ChIP-seq from induced pluripotent stem cell (ENCSR655HDE)

Project description:Chip-Seq on PGP1 iPSC-human (fragmentation date:2015-09-03) For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-03-12 | GSE96293 | GEO

ChIP-seq from induced pluripotent stem cell (ENCSR447FVP)

Project description:Chip-Seq on PGP1 iPSC-human (fragmentation date: 2015-09-03) For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-03-12 | GSE96177 | GEO

DRIP-sequencing U2OS

Project description:DRIP-sequencing U2OS

| PRJNA533125 | ENA

U2OS shE4F1 transcriptome

Project description:U2OS shE4F1 transcriptome

| PRJNA605446 | ENA

Transcriptomics profile of polyQ expressing U2OS cells and clofazimine treated polyQ expressing U2OS cells

Project description:To better understand the mechanism by which CFZ impacts polyQ toxicity, we conducted a transcriptomic analysis in polyQ94-EGFP expressing U2OS (5μM, 8 days). Data from a transcriptomics experiment in polyQ94-U2OS cells treated with CFZ (5 μM, 8day) was compared to a DMSO-treated control.

2023-05-11 | GSE222758 | GEO

Supplementary Dataset 11b - SILAC data for HEK293T-Subtiligase-Y217K-TM Pervanadate treated vs untreated

Project description:This dataset contains SILAC data for HEK293T-Subtiligase-Y217K-TM cells, pervanadate treated vs untreated. In Q20180417-03 and Q20180417-05, light cells were pervanadate treated and heavy cells were the control. In Q20180417-07 and Q20180417-09, heavy cells were pervanadate treated and light cells were the control.

2020-02-21 | MSV000084994 | MassIVE

ChIP-seq from MCF-7 (ENCSR511PAE)

Project description:Reverse Crosslink ControlChIP-seq on human MCF-7 (fragmentation date 03-05-14) For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2017-03-12 | GSE96204 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data